First study of infliximab treatment in patients with chronic obstructive pulmonary disease (Q47785823)

5 February 2018

title

First study of infliximab treatment in patients with chronic obstructive pulmonary disease (English)

1 reference

5 February 2018

chronic obstructive pulmonary disease

main subject

1 reference

Dirkje S Postma

1 reference

5 February 2018

author name string

Hester van der Vaart

1 reference

5 February 2018

Gerard H Koëter

1 reference

5 February 2018

Henk F Kauffman

1 reference

5 February 2018

Nick H T ten Hacken

1 reference

5 February 2018

language of work or name

English

0 references

publication date

3 June 2005

1 reference

5 February 2018

American Journal of Respiratory and Critical Care Medicine

published in

1 reference

5 February 2018

volume

172

1 reference

5 February 2018

issue

1 reference

5 February 2018

page(s)

465-469

1 reference

5 February 2018

Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study

cites work

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-147OC

Ongoing airway inflammation in patients with COPD who do not currently smoke

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-147OC

Chronic obstructive pulmonary disease * 12: New treatments for COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-147OC

Tumor necrosis factor-alpha drives 70% of cigarette smoke-induced emphysema in the mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-147OC

Oxidative stress and TNF-alpha induce histone acetylation and NF-kappaB/AP-1 activation in alveolar epithelial cells: potential mechanism in gene transcription in lung inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-147OC

Tumor necrosis factor alpha (TNF-alpha)-induced cell adhesion to human endothelial cells is under dominant control of one TNF receptor type, TNF-R55.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-147OC

Tumor necrosis factor-alpha levels and weight loss in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-147OC

Association of tumor necrosis factor-alpha gene promoter polymorphism with low attenuation areas on high-resolution CT in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-147OC

A polymorphism in the tumor necrosis factor-alpha gene promoter region may predispose to a poor prognosis in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-147OC

Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-147OC

Increased resting energy expenditure is related to plasma TNF-alpha concentration in stable COPD patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-147OC

Elevated TNF-alpha production by peripheral blood monocytes of weight-losing COPD patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-147OC

Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-147OC

Construction and initial characterization of a mouse-human chimeric anti-TNF antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-147OC

Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-147OC

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-147OC

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-147OC

Development, validity and responsiveness of the Clinical COPD Questionnaire

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-147OC

Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-147OC

Total free living energy expenditure in patients with severe chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-147OC

Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-147OC

Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failu

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-147OC

Effect of a chimeric antibody to tumor necrosis factor-alpha on cytokine and physiologic responses in patients with severe sepsis--a randomized, clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-147OC

Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-147OC

Airway inflammation and hyperresponsiveness to adenosine 5'-monophosphate in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-147OC

10.1164/RCCM.200501-147OC

21 January 2018

Identifiers

DOI

1 reference

5 February 2018

1 reference

5 February 2018